Mepolizumab Reduces Healthcare Costs & Work Impairment in Asthma
Okay, here’s a breakdown of the provided text, focusing on key information and summarizing the main points.
Overall Topic: The long-term economic and clinical benefits of mepolizumab as an add-on therapy for severe eosinophilic asthma.
Key findings (from the REALITI-A study):
* Reduced Healthcare Resource Utilization (HCRU): Mepolizumab led to ample and sustained reductions in:
* Asthma-related hospitalizations (59-64% reduction, P* < .001)
* Emergency Department (ED) visits (59-64% reduction, *P < .001)
* Outpatient visits (59-64% reduction, P* < .001)
* Overnight hospital stays decreased substantially over 24 months (from 2.4 to 0.5 per patient).
* Improved Work Productivity (WPAI): Patients experienced a 74% relative reduction in overall work impairment after 24 months. This was driven by significant decreases in presenteeism (being impaired while at work).
* Study Design: The REALITI-A study was a prospective study involving 822 adult patients with severe asthma who were newly starting mepolizumab treatment. It compared HCRU and WPAI outcomes for 24 months *after treatment initiation to the 12 months before treatment.
* Patient Population: The study population was representative of real-world severe asthma patients,with a mean age of 54 and a high baseline exacerbation rate (4.4 events per year).
Context & Significance:
* Severe asthma is economically burdensome due to hospitalizations and lost productivity.
* The REALITI-A study adds to existing evidence (clinical trials and claims data) supporting the value of mepolizumab in reducing the burden of severe asthma.
* The benefits observed in the study were sustained over a 2-year period.
in essence, the text argues that mepolizumab is a valuable long-term treatment for severe asthma, not only improving patient health but also reducing healthcare costs and improving work productivity.
Additional Notes from the HTML Snippet:
* there’s an image included with a caption about the study’s findings.
* Superscripts () are used to cite references (2, 3, and 1).
* The text is formatted with <p> tags for paragraphs and <span> tags for text within the caption.
* The HTML includes some metadata related to Astro, a web framework, and client-side JavaScript loading. This is not relevant to the content itself.